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Abstract:
Background: Primary immunodeficiency diseases (PID) comprise a group of  more than 300 diseases that affect development 
and /or function of  the immune system. 
Objectives: The aim of  this study was diagnosis of  PID among a suspected group of  neonates and infants within the first six 
months of  life as well as identifying the warning signs of  PID characteristic to this period. 
Method: Fifty neonates presenting with warning signs of  PID were enrolled in the study. 
Results: The study revealed that twenty six patients (52%) were diagnosed with Primary Immunodeficiency, T cell/combined 
immunodeficiency were noted as the most common PID class (88.5%) with fourteen T-B-SCID patients (70%) and six T-B+ 
SCID patients (30%), phagocytic disorders were estimated to be 7.7% while 3.8% were unclassified immunodeficiency. The 
mean age of  presentation for PID group was 1.42±1.38 months with a diagnostic lag of  3.08±1.78 months. Consanguinity was 
positive in 76.9% of  the PID group. Lower respiratory tract infections ,persistent fungal infections and lymphopenia were the 
most significant warning signs for diagnosing PID with a p value of  (0.01). Combined, lower respiratory tract infections, fungal 
infections and lymphopenia were 12.3 times more likely to be associated with PID. 
Conclusion: Focused screening in high risk neonates proved to be a valuable tool for diagnosis of  PID disorders.
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Introduction 
Primary immunodeficiency diseases (PID) comprise a 
group of  more than 300 distinct diseases arising from 
different genetic abnormalities that affect development 
and/or function of  the immune system1. The exact prev-
alence of  PID is uncertain because of  lack of  screening 
in newborns, national registries or reporting by govern-
ment health surveys in many countries2; however PID 
prevalence of  approximately 1:10.000 was reported in 
Australian, North American and European populations3. 
It is anticipated that high rates of  consanguinity and in-
breeding will lead to a higher incidence of  autosomal re-
cessive disorders4,5, however there is paucity of  data on 
prevalence of  PID in developing countries and the Mid-
dle East region. Pilot studies reported the presence of  
autosomal recessive disorders in abundance and empha-
sized the late diagnosis5, Previous studies in Egypt have 
estimated a presentation in the first year of  life among 
29.7% of  total cases diagnosed with PID4.
 
The PID clinical symptoms have a wide range of  pre-
sentations that could be challenging during practice. The 
most commonly known PID disorder presenting in the 
neonatal period is Severe Combined Immunodeficiency 
(SCID); these patients usually present within the 1st six 
months of  life with failure to thrive, chronic diarrhea per-
sistent oral thrush, skin rash, pneumonia, sepsis, dissem-
inated BCG infection6. Other PID disorders may equally 
present in the neonatal period but are unrecognized due 
to lack of  awareness e.g. Di-George syndrome, hyper 
IgE syndrome1. Diseases of  immune dysregulation eg, 
Familial hemophagocytic lymphohistocytosis (FHL) and 
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Immune Dysregulation Polyendocrinopathy Enteropathy 
X-Linked (IPEX) also commonly present before the age 
of  6 months7.
The study aimed at diagnosis of  PID among a suspected 
group of  neonates and infants within the first six months 
of  life as well as identifying the warning signs of  PID 
characteristic to the neonatal period and early infancy.
 
Methodology
The study was conducted at Cairo University Specialized 
Pediatric Hospital, a tertiary referral center specialized in 
Primary Immunodeficiency Disorders. Informed consent 
was obtained from patients' guardians and Institutional 
review board approval waa obtained. The study includ-
ed fifty cases  recruited over a period of  one year (from 
June 2015 through June 2016) of  neonates and infants 
presenting with clinical manifestations suggestive of  pri-
mary immunodeficiency diseases(PID) within the first six 
months of  life.
Patients with the following features suggestive of  PID 
were included:
-  Recurrent /Persistent infections: unresolving pneumo-
nia, recurrent pneumonia, sepsis, systemic candidiasis, 
deep seated abscesses that necessitate drainage.
- Patients presenting with other features suggestive of  
SCID (profound failure to thrive, persistent diarrhea, ab-
sent thymus).
-  Patients with signs of  Immune dysregulation (early in-
flammatory bowel disease, early onset of  diabetes melli-
tus, autoimmune disorders as hepatitis, failure to thrive).
- Male patients with eczema and persistent thrombocy-
topenia associated with infections suggestive of  Wiskott 
Aldrich syndrome.
- Previously affected or possibly affected siblings with 
PID.
- Previous unexplained sibling deaths at young age.
- Persistent Lymphopenia with unexplained cause: abso-
lute lymphocyte count < 3000/mm3 in blood film. 
- Patients with persistent neutropenia with unexplained 
cause: the absolute neutrophil count <1500/mm3 .
- Patients with delayed separation of  the umbilical stump 
(more than one month) /high leukocyte count (>30,000/
mm3) suggestive of  Leukocyte adhesion defect.
Cases with Infections explained by other causes e.g.( sec-
ondary to congenital heart disease without associated 
immunodeficiency, neurological disorders) and or failure 
to thrive due to other disorders were excluded from the 
study. 
The patients were subjected to detailed history taking and 
examination. Laboratory investigations included com-
plete differential blood counts, Peripheral blood lympho-
cytes were evaluated and surface-stained with anti-CD3 
as pan-T marker, anti-CD4 for T helper lymphocytes, 
anti-CD8 for cytotoxic T cells, anti-CD19 or anti-CD20 
as pan B markers, anti-CD16, and anti-CD56 for Natu-
ral killer cells by flow cytometry. Specific memory/naϊve 
markers as CD45RA, CD45RO were used for determi-
nation of  memory versus naïve T cells and  IgM IgD 
CD27 for  B cells maturation  when indicated. Serum im-
munoglobulin levels were determined by nephelometry. 
Neutrophils function was assessed by Dihydrorhodamine 
test when Chronic granulomatous disease was suspect-
ed. Some of  the patients once diagnosed with PID un-
derwent more extensive testing like molecular testing as 
Whole exome sequencing when possible.
Statistical methods 
Categorical variables presented by number and presented. 
They were assessed by chi-square or Fischer exact test 
when appropriate. Odds ratio were calculated with 95% 
confidence interval continuous variables presented by 
mean and standard deviation) SD). They were compared 
by t-student test. In all tests, p values were considered 
significant if  less than 0.05.
Results
The study population included twenty three females 
(46%) and twenty seven (54%) males. Thirty three (66%) 
infants were born to consanguineous parents while sev-
enteen (34%) were born to non-consanguineous parents. 
Regarding the presenting warning signs indicating screen-
ing in the studied group collectively (n=50); need for 
intravenous antibiotics to clear infections was found in 
thirty eight patients (76%) , thirty four patients (68%) suf-
fered from persistent or recurrent lower respiratory tract 
infections (pneumoniae) and persistent fungal infections 
in the form of  oral and/or diaper moniliasis were found 
in twenty four patients (48%).Ten patients (20%) had his-
tory of   previously affected family members{two families 
were consanguineous and eight families were non con-
sanguineous)}. Recurrent/deep skin or organ abscesses 
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were found in 10 (20%) patients. 9 patients (18%) had 
serious infections, 9 patients (18%) were suffering from 
failure to thrive, recurrent otitis media was present in 6 
patients (12%) and 2 patients (4%) were on prolonged 
courses of  antibiotics (more than two months) with little 
effect.
1 patient had 6 warning signs, 1 patient had 5 warning 
signs, and 16 patients had 4 warning signs while 10 patients 
had 3 warning signs. 14 patients had 2 warning signs, and 
8 patients had 1 warning sign (they were screened based 
on positive family history of  PID). 
The study population was screened and divided into two 
groups: Primary Immunodeficiency Disorders (PID) 
group which included 26 patients and Non-Immunodefi-
ciency Disorders (Non PID) group including 24 patients. 
There was no statistical difference between PID and Non 
PID groups regarding age of  presentation while there 
was a significant statistical difference in the age of  diag-
nosis between both groups with a later age at diagnosis 
for PID group (P value 0.04). The mean age of  first pre-
sentation in the PID group was (1.42 months, SD ±1.38) 
whereas the mean age of  diagnosis was (4.50 months, SD 
±1.81) with a diagnostic lag of  (3.08months, SD±1.78) in 
the PID group. 
Regarding the comparison of  the warning signs between 
PID and non PID  groups, lower respiratory tract infec-
tions and persistent fungal infections both  were signifi-
cant warning signs regarding PID patients with a P val-
ue of   (<0.01). Lower respiratory tract infections had a 
sensitivity of  85%, a specificity of  50% while persistent 
fungal infections had a sensitivity of  69%, a specificity of  
75%. Lymphopenia had a sensitivity of  69% and a speci-
ficity of  83%, it was also a significant marker on compar-
ing PID and Non PID groups with a p value of  <0.01. 
Lower respiratory tract infections increased the chances 
of   being diagnosed with PID 5.5 more times than pa-
tients with no history of  lower respiratory tract infections 
while fungal infections increased the risk of  being diag-
nosed as PID patient 6.8 more times than patients with 
no fungal infections .Lymphopenia was 15 times more 
likely associated with having PID whereas patients with 
combined lymphopenia, fungal infection and lower respi-
ratory tract infections were 12.3 times more likely to be 
diagnosed with a PID disorder .
The Primary Immunodeficiency group included 26 pa-
tients. 23 patients were diagnosed with Combined Im-
munodeficiency Disorders; 20 cases were diagnosed as 
Severe Combined Immunodeficiency Disorders (SCID), 
including 2 cases as Omenn Syndrome, 1 patient was di-
Figure(1): Percentage and Number of warning signs among the study population
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agnosed as Hyper Immunoglobulin E syndrome (HIES), 
one patient was diagnosed as Major histocompatibility 
complex (MHC) class II deficiency and 1 patient was di-
agnosed as isolated CD4 lymphopenia. 
2 patients were diagnosed as phagocytic defects. 1 patient 
was diagnosed as Leukocyte Adhesion Deficiency (LAD) 
while the other 1 was diagnosed with Chronic Granu-
lomatous Disease (CGD). 1 patient was categorized as 
unclassified Primary Immunodeficiency (suspected to be 
Mendelian Susceptibility to Mycobacterial disease-MSMD). 
Severe combined immunodeficiency group was further 
classified according to B cell counts into T-B-SCID and 
T-B+ SCID. T-B- SCID constituted 70% (n=14) of  pa-
tients and T- B+ made up the remaining 30% (n=6). 
Out of  the 20 SCID cases, 10 were tested for the genetic 
mutations and diagnoses included; 3 cases of  Janus Ki-
nase 3 (JAK3) Deficiency,2 cases of  Adenosine Deami-
nase(ADA) deficiency, 2 cases of  Recombinase Activat-
ing Gene(RAG) mutations and a single case of  Artemis 
(DCLREIC),IL7R and IL2RG mutations .
The non-PID group included 9 patients with CMV in-
fection, 4 with cow’s milk allergy, 3 with malnutrition 
(improved with rehabilitation), 2 with Cystic Fibrosis, 1 
with metabolic error. 5 had no pathological diagnosis to 
explain symptoms and only suffered those infections. 
Table 1. Clinical characteristics of PID group 
No Sex Age of diagnosis 
(month) 
 
Age of onset of 1st symptoms 
(month) 
 Clinical manifestations Diagnosis 
1 M 1.3 1.3 Pneumonia, fungal infections, sibling death.  SCID (ADA) 
2 F 0.5 0.5 Previous affected sibling. SCID (JAK3) 
3 M 6 0.3 Pneumonia, fungal infections. SCID (IL7R) 
4 F 0.3 0.3 Previous affected sibling, sibling death. SCID(DCLRE1C) 
5 F 6 0.6 Failure to thrive, otitis media, fungal infection.  SCID(JAK3) 
6 M 6 3 Pneumonia, evidence of fungal infection, otitis media, family death due to infection. SCID(IL2RG) 
7 F 5 0.2 Pneumonia, fungal infection, sibling death. SCID (Unident) 
8 M 3 0.2 Pneumonia, fungal infection, sibling death, family death. SCID (RAG1) 
9 M 6 5 previous affected sibling, Pneumonia, fungal infection, family death, axillary lymphadenopathy 
after BCG vaccine, sibling death. 
SCID(RAG2) 
10 M 2 0.2 Pneumonia, sepsis, Pericardial effusion, family death.  SCID (ADA) 
11 F 3 0.5 Failure to thrive, Pneumonia, family death, sibling death.  SCID(Unident) 
12 M 6 1 Pneumonia, fungal infection, organomegaly , sibling death. SCID(Unident) 
13 F 3 2 Pneumonia, fungal infection, deep seated abscesses. SCID(Unidenti) 
14 F 6 2 Failure to thrive, Pneumonia, fungal infection. sibling death.  SCID(Unident) 
15 F 6 4 Failure to thrive, Pneumonia, evidence of fungal infection, recurrent of admission  SCID (JAK3) 
16 F 5 3 Pneumonia, fungal infection, organomegaly, sibling death.  SCID(Unident) 
17 M 5 0.3 Pneumonia, fungal infection, deep seated abscesses, otitis media, sepsis, organomegaly,  SCID(Unident) 
18 M 5 0.3 Pneumonia, fungal infection, deep seated abscesses .  SCID(Unident) 
19 F 6 2 Pneumonia, fungal infection, skin rash, siblingdeath. Omenn syndrome 
20 F 4 2 Pneumonia, fungal infection, Exfoliative skin rash. Omenn syndrome 
21 F 6 4 Failure to thrive, CNS infection, pneumonia, diarrhea and paralysis after Polio vaccine MHC class II 
(RFXANK) 
22 M 6 1.3 Pneumonia, fungal infection, deep seated abscesses, meningitis, sepsis, family death.  Isolated CD4 
lymphopenia 
23 M 5 1 Pneumonia, fungal infection, otitis media. Hyper IgE 
24 M 5 1.5 Recurrent deep seated abscesses.  CGD 
25 M 5 0.3 Ulcers, delayed umbilical stump separation, severe omphalitis, Pneumonia, otitis media, 
organomegaly 
LAD 






SCID:  Severe  Combined Immunodeficiency Disorders. 
HIES: Hyper Immunoglobulin E syndrome.  
MHC class II: Major histocompatibility complex class II deficiency. 
LAD: Leukocyte Adhesion Deficiency.   
CGD: Chronic Granulomatous Disease. 
CNS: Central nervous system. 
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Regarding the immunization history: 2 of  the PID pa-
tients were not vaccinated and 24 were vaccinated with 
both polio and BCG vaccines prior to diagnosis. 1 patient 
developed diarrhea and acute flaccid paralysis (case No 
21) following polio vaccination. First stool sample analy-
sis revealed excretion of  Sabin like SL3 which might have 
evolved later into Immunodeficiency-related vaccine-de-
rived poliovirus (iVDPV) case, yet she passed away soon 
thereafter. Another patient developed BCGoma (case No 
26) and 1 patient developed left axillary lymphadenopa-
thy resolving spontaneously, results were statistically in-
significant .
On comparing the Complete blood counts for both 
groups results showed a significant statistical difference 
with a p value of  (0.001) for lymphopenia and absolute 
neutrophil count with a p value of  (0.004), neutropenia 
was found in 14 patients (28%) of  the studied group, 8 of  
them were PID and 6 were Non PID .The while White 
blood cells, platelet count, percentage of  (Monocyte, Ba-
sophil, Eosinophil) showed no statistical significant val-
ues across the groups. 
 
Table (2) Comparison  between Primary Immunodeficiency Disorders group versus non primary 
 immunodeficiency groups regarding complete blood picture: 
 
Lab results PID  Non PID   
  Mean SD± Mean SD± P -value 
PLT 370923.08 226433.73 370666.67 245018.66 0.997 
WBCs 9.32 10.61 12.93 8.08 0.185 
Neutrophil % 0.50 0.19 0.33 0.20 0.004* 
Absolute neutrophil 
count  
5593.84 7564.78 4220.57 3630.19 0.422 
Lymph % 0.32 0.17 0.55 0.19 0.000* 
Absolute lymph 
count 
2731.72 2768.07 5631.48 3243.44 0.001* 
Monocyte % 0.11 0.07 0.11 0.16 0.924 
Basophil % 0.01 0.01 0.00 0.00 0.064 
Eosinophil % 0.04 0.09 0.02 0.03 0.360 
PID: Primary Immunodeficiency Disorders. 
Non PID:  Non Primary Immunodeficiency Disorders. 
SD: standard deviation. 
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Figure (2 ): Comparison between Primary Immunodeficiency Disorders group 
versus non primary immunodeficiency groups regarding lymphocyte percentage. 
On comparing the CD counts between both groups 
regarding the mean and SD± of  values of  CD3, CD4, 
CD8, CD19, CD56 absolute number and percentage 
(reflective of  T cell function) results showed significant 
statistical difference between the two groups in the per-
centage  and the absolute numbers of  (CD3, CD4, CD8, 
CD19, CD56) with a p value of   (<0.01). 
As for the outcome of  the studied group; Eleven of  the 
Primary immunodeficiency patients died (42.3%), nine 
patient were still alive and symptomatizing (34.6%), one 
received bone marrow transplantation and is alive and 
well, while six patients were lost to follow up (23%). 
Discussion
PIDs can be inherited in different patterns; the autoso-
mal recessive (AR) pattern is the most common form of  
inheritance in patients born to consanguineous parents1. 
A previous study over a five year period from a tertiary 
PID referral center in Egypt demonstrated clearly that in 
highly consanguineous populations, autosomal recessive 
forms of  PID disorders prevail and may also have pecu-
liar characteristics pertaining to presentations and under-
lying genetic mutations8.
In our cohort consanguinity was highly positive among 
PID patients, a finding reported by other Middle Eastern 
countries, including Qatar, Iran, Kuwait, and other North 
African countries5,9. 
Males were affected more than females, a trend seen in 
other parts of  the world, including Europe and India10,11.
The ages reported in the present study were earlier than 
the previously estimated12, in Zagazig who reported that 
the median onset age of  symptoms was 7 months (range, 
1–84 months) and the median age at diagnosis was 24 
months (3–120 months). Zeng et al.13 in their study from 
South China reported a median age at diagnosis of  10 
months range (2-159 months). Hadizadehet al.14 based 
on twelve studies, again reported a higher age at diag-
nosis of  PID patients which ranged from 12.0 to 74.5 
months. The relative younger age of  presentation and di-
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agnosis reported hereby may be attributed to the focused 
screening of  neonates, the high number of  SCID patients 
among our cohort and or increased awareness as some 
cases had previous affected family members.
The lag in diagnosis in the present study (3.08±1.78 
months) was similar to a pervious study conducted in 
Ain Shams University9 who reported a diagnostic lag of  3 
months while it was less than what was reported in other 
countries like Tunisia (18 months), Morocco (24 months) 
and France (1 year)15,16,17.
Patients were assessed for warning signs of  PID accord-
ing to the criteria established by the Jeffrey Modell Foun-
dation. However, the warning signs carry limitations as 
a screening tool because they may fail to identify some 
patients with serious PIDs, as recently reported18,19. Be-
cause other clinical symptoms can raise the suspicion of  
PID, in Sweden, Gruber et al has extended the inclusion 
criteria beyond the 10 warning signs to incorporate addi-
tional symptoms including recurrent fever or fever with 
duration of  more than 6 weeks, and an excessive number 
of  upper respiratory tract infections (>8 per year)20. In a 
study done by Brodszk et al.21, recurrent otitis media was 
the most common warning sign of  PID and therefore the 
inclusion criteria were expanded .
Respiratory symptoms represent an important marker 
pointing the attention toward PIDs22. In our study, low-
er respiratory tract infections were the most significant 
warning sign for diagnosing PID as it was reported in 
22/26 patients. Lower respiratory infections had a sensi-
tivity of  85% and a specificity of  50%. Consistent with 
our finding, eighty nine patients were studied in Argen-
tina and the main clinical manifestation among patients 
with PID was respiratory tract infections23, and also in 
Korea where the most common first manifestation in 
PID patients was pneumonia24. 
Tenacious fungal infections are commonly reported in the 
context of  acquired conditions (HIV infection,  immu-
nosuppressive therapies, prolonged antibiotic therapies, 
diabetes mellitus) or various Primary Immunodeficiency 
Disorders  as with severe combined immunodeficiencies 
(SCID) and  with combined immunodeficiencies (CID)25. 
In our study persistent fungal infections in the form of  
tenacious oral and/or diaper moniliasis were found in 
twenty four patients (48%) and it was a significant warn-
ing sign regarding PID patients with a sensitivity of  69% 
and a specificity of  75%.
The warning sign of  having a family member with a 
known immunodeficiency is advocated as one of  the 
three most important signs for identifying patients with 
PID19. However, in our study group, a positive family his-
tory was reported only in 3/26 patients with PID.  
In our study the need for intravenous antibiotics to clear 
infections was observed in 22 out of  26 PID patients 
while failure to thrive was reported in 6 patients. Similar 
to our findings, need for intravenous antibiotics to clear 
infections has been identified as one of  three key warning 
signs for PID in South Africa26 while in a study done in 
Guanajuato, Mexico by Guerra et al.27, which included 26 
PID cases, need for intravenous antibiotics  was the most 
frequent warning sign (19/26 = 73.08%) followed by  two 
or more pneumonias within 1 year (14/26 = 53.85%), 
and failure of  an infant to gain weight or grow normally 
(12/26 = 46.15%). 
In Egypt, a study by  Reda et al.9 of  the most frequent 
warning sign among patients with PID ,the need for 
intravenous antibiotics came first. Failure to thrive was 
more frequent in the categories of  combined T- and 
B-cell immunodeficiencies and predominantly antibody 
deficiency. Recurrent deep-skin and organ abscesses and 
deep-seated infections were significantly more frequent in 
the category of  congenital defects in phagocyte number, 
function, or both. In Zagazig, Egypt another study done 
by A Hussien et al12, over a period of  two years includ-
ing 50 patients found pneumoniae, bronchitis and otitis 
media were the most common presentations in PID pa-
tients .Recurrent severe infections as pneumonia, chronic 
diarrhea, and failure to thrive are commonly thought of  
as classic symptoms of  PID and patients with combined 
lower respiratory tract infections, fungal infections and 
lymphopenia were 12.3 times more likely to be diagnosed 
with a PID disorder.
Primary Immunodeficienies were reported in 52% of  the 
study group; T cell/combined immunodeficiencies were 
noted as the most common PID class (88.5%) with four-
teen T_B_SCID patients (70%) and six T-B+ SCID pa-
tients (30%). In a previous study in Egypt, combined im-
munodeficiency disorders (CID) constituted around 30% 
of  all the categories reported while CID with syndromic 
disorders represented around 46.8 %. Studies from oth-
er Arab countries showed similar results. In Tunisia, the 
percent of  CID was 28.5 % among other PIDs diagnosed 
while in Saudi Arabia, the percentage was higher (59.7 
%)5,28,29,8.
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Other countries reported a high prevalence of  combined 
disorders however it was not the most common category 
as in Kuwait, where CID represented 21%, following the 
antibody defects. In Oman, phagocytic disorders were re-
ported as the most common PID category30,31. In Iran; 
predominantly antibody deficiencies were the most com-
mon subcategory of  PID (32.3 %) followed by combined 
immunodeficiencies (22.3 %)32.
The present study revealed that SCID constituted the ma-
jor category of  PID disorders among our studied patients. 
A previous study from the largest PID referral center in 
Egypt documented a high incidence of  SCID with a rel-
atively late age at diagnosis and a diagnostic lag of  sev-
eral months, among the 140 cases diagnosed with severe 
combined immunodeficiency (SCID)/Omenn syndrome, 
(50.5 %) cases were diagnosed with T-B-SCID,(38.5 %) 
with T-B + SCID, and 10 were diagnosed with Omenn 
syndrome (11 %)8. A study comparing SCID patients di-
agnosed in Kuwait and USA revealed a different age of  
onset and different molecular causes, which highlights 
the importance of  newborn screening33.
Regarding North Africa, Morocco, as well as Tunisia, data 
showed that among T-B+ SCIDs, only a minority had 
X-linked form, while autosomal recessive forms as inter-
leukin 7 receptor  alpha chain (IL7Rα) expression defect 
and janus kinase 3 (Jak-3) deficiencies were observed in 
more patients ((Barbouche et al., 2011). RAG mutations 
were confirmed to be not uncommon in the Egyptian 
SCID population as previously reported by Meshaal et al. 
(2015).Immunophenotyping of  30 SCID in Morocco pa-
tients showed a predominance of  T−B−SCID (63.3%), 
with T-B-NK+ being the most common subtype (46.7 
%)35.
Obligatory Immunization Program in Egypt includes 
oral polio vaccine (OPV) and BCG vaccine at birth.Left 
axillary lymphadenopathy, BCGoma, diarrhea and acute 
Flaccid Paralysis were complications observed in some 
cases of  PID patients in our study after live attenuated 
vaccinations. These vaccines may be lethal and cause 
severe/disseminated disease in patients with immuno-
deficiency patients36. Wild poliovirus type-2 has been 
eradicated and use of  live type-2 vaccine has been ter-
minated globally, all type-2 polioviruses are under strict 
laboratory containment protocols. Re-emergence may 
arise from prolonged asymptomatic excretion of  polio-
virus by primary immune deficient (PID) patients37. Pa-
tients with primary immune deficiency disorders (PIDD) 
who receive oral poliovirus vaccine (OPV) may transmit 
immunodeficiency associated vaccine-derived poliovirus-
es (iVDPVs) and cause paralytic Polio38. For this reason, 
oral polio vaccine (OPV) and BCG vaccination must be 
avoided in all the severe forms of  PID39,40,41. In families 
with suspicious family history, vaccines should be with 
held till screening occurs.
As patients with PID suffer from recurrent infections 
definite treatment with bone marrow transplantation or 
gene therapy is warranted but unfortunately is limited by 
availability of  matched donor and the cost of  this thera-
py. In our study one SCID patient was transplanted, dis-
charged and completely cured.
In order to enhance the overall understanding of  PID 
for the community and clinicians, it is not only necessary 
to recognize and diagnose the disease early, but also to 
improve the level of  treatment. Diagnosing the patients 
early gives them a better chance and a better quality of  
life before they succumb to infections. It also provides 
precious time for matching and administrative processes 
needed for treatment in a resource limited country.
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